Stockscreener 앱 받기
1.78
10.56%
0.17
시간 외 거래:
1.79
0.01
+0.56%
전일 마감가:
$1.61
열려 있는:
$1.67
하루 거래량:
3.34M
Relative Volume:
1.45
시가총액:
$209.45M
수익:
$1.55M
순이익/손실:
$-63.06M
주가수익비율:
-2.2365
EPS:
-0.7959
순현금흐름:
$-49.45M
1주 성능:
+35.88%
1개월 성능:
+12.66%
6개월 성능:
-11.00%
1년 성능:
+172.63%
1일 변동 폭
$1.61
$1.80
1주일 범위
$1.245
$1.80
52주 변동 폭
$0.63
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.78 | 189.44M | 1.55M | -63.06M | -49.45M | -0.7959 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-09-11 | 개시 | Wells Fargo | Overweight |
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Will Freshworks Inc. stock benefit from sector rotationWeekly Profit Recap & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Buybacks Report: Does Milestone Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Scalable Portfolio Growth Methods - baoquankhu1.vn
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Institution Moves: Is Milestone Pharmaceuticals Inc undervalued by DCF analysis2026 Earnings Impact & Free Community Consensus Stock Picks - baoquankhu1.vn
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Trails Edge Capital Partners, LP Acquires 5,333,333 Shares in Mi - GuruFocus
Milestone Pharmaceuticals Announces that CARDAMYST (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - Bitget
Milestone Pharmaceuticals (MIST) Secures Formulary Inclusion for Cardamyst - GuruFocus
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - The Manila Times
Express Scripts adds new PSVT nasal spray to national formularies - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Milestone Pharmaceuticals gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Published on: 2026-03-28 09:41:33 - baoquankhu1.vn
Published on: 2026-03-28 10:15:13 - baoquankhu1.vn
Milestone Pharmaceuticals Stock: Trails Edge Discloses 4.3% Stake Amid Q4 Earnings Anticipation - AD HOC NEWS
Trails Edge files amended 4.3% stake disclosure in Milestone Pharmaceuticals (MIST) - Stock Titan
Aug Chart Watch: Is Milestone Pharmaceuticals Incs ROIC above industry averageForecast Cut & Daily Stock Trend Watchlist - baoquankhu1.vn
Milestone Pharmaceuticals Faces Increased Risk Amid Mixed Technical and Valuation Signals - Markets Mojo
Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Tuesday - MarketBeat
Milestone Pharmaceuticals Inc. (MIST) GC reports 400,000-share stock option - Stock Titan
Equities Analysts Issue Forecasts for MIST FY2028 Earnings - marketbeat.com
Milestone Pharmaceuticals Faces Financial Challenges amidst Market Shifts - timothysykes.com
Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals - The Globe and Mail
MIST PE Ratio & Valuation, Is MIST Overvalued - Intellectia AI
Milestone Pharmaceuticals (NASDAQ:MIST) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Why Milestone Pharma Stock Is Taking A Dive Today - Sahm
Why Milestone Pharma stock is taking a dive today - MSN
How does Milestone Pharmaceuticals Inc compare to its peersIndex Update & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highl - GuruFocus
S P Trends: Does Milestone Pharmaceuticals Inc have consistent dividend growth2026 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Buyback Watch: What is the long term forecast for Milestone Pharmaceuticals Inc stock2026 Winners & Losers & Verified Momentum Stock Alerts - baoquankhu1.vn
Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Milestone Pharma Faces Earnings Hurdles Amidst Market Fluctuations - StocksToTrade
Milestone: Early CARDAMYST Launch Progress and Solid Cash Position Underscore Buy Rating and $8 Target - TipRanks
Missing Data on MIST: Insights and Analysis - timothysykes.com
Milestone Pharmaceuticals Reports 2025 Financial Results and Launch of FDA-Approved CARDAMYST Nasal Spray for PSVT - Minichart
Milestone Pharmaceuticals 2025 Annual Report: CARDAMYST™ (etripamil) Launch, Business Overview, and Key Risks - Minichart
Milestone Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Milestone Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Milestone Pharmaceuticals meets EPS forecast, stock dips - Investing.com
Milestone Advances CARDAMYST Launch After Landmark PSVT Approval and Bolsters Cash Runway - TipRanks
Milestone Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Milestone Pharmaceuticals (MIST) Reports Strong Financial and Ma - GuruFocus
Milestone Pharmaceuticals reports Q4 EPS (16c), consensus (18c) - TipRanks
Milestone Pharmaceuticals: Q4 Earnings Snapshot - Barchart.com
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT - The Manila Times
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
1.75%
자본화:
|
볼륨(24시간):